查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863570

单细胞多组体学市场：2025-2032年全球预测（依产品、技术、应用、最终使用者和工作流程划分）

Single-Cell Multi-Omics Market by Product, Technology, Application, End User, Workflow - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，单细胞多组体学市场将成长至 74.7 亿美元，复合年增长率为 11.27%。

关键市场统计数据
基准年 2024 31.8亿美元
预计年份：2025年 35.4亿美元
预测年份 2032 74.7亿美元
复合年增长率 (%) 11.27%

本书权威地概述了单细胞多组体学如何发展成为一个多学科平台，并重塑了研究重点和转化研究流程。

单细胞多组体学已从一个小众研究领域发展成为现代生命科学的基石，重塑了研究人员揭示细胞异质性和生物系统的方式。近年来，调查方法的进步提高了基因组、转录组、蛋白质组和空间层面的分辨率，从而能够对组织内、发育过程中以及疾病状态下的细胞进行整合观察。因此，这一系列技术能够支持更广泛的实验目标，从生物标记发现和机制研究到标靶识别和药物优化，使其成为学术界和工业界不可或缺的工具。

同时，技术应用趋势也在转变。早期采用者专注于概念验证实验和基准调查方法，而目前采用者则更注重通量、可重复性和能够提供可操作洞见的端到端工作流程。这种成熟趋势推动了对仪器、耗材、样本和样品製备套件以及利用人工智慧和先进生物资讯技术的复杂数据分析解决方案的投资。因此，相关人员不仅需要关注仪器性能，还必须考虑供应商生态系统、资料互通性和监管要求。

从发现到应用的转变带来了新的营运复杂性和策略决策。各机构必须权衡高解析度资料的需求与通量、成本和下游分析能力。此外，湿实验室科学家、计算生物学家和临床团队之间的多学科合作至关重要。本文为深入探讨技术转折点、监管和贸易阻力、特定领域的机会、区域差异以及为希望利用单细胞多体学技术进步的领导者提供的策略建议奠定了基础。

这是一个关键的技术和生态系统转折点，它将加速生命科学工作流程中的多模态整合、吞吐量和分析复杂性。

单细胞多组体学领域正经历着一场变革性的转变，这主要得益于仪器技术、化学和计算分析的融合。仪器供应商正致力于开发高通量、整合的分析方法，以同时捕捉DNA、RNA、蛋白质和空间讯息，从而降低实验总成本并缩短获得有效结果所需的时间。同时，试剂和样品製备化学技术的进步也提高了捕获效率并降低了技术变异性，从而增强了不同研究间结果的一致性和可重复性。

在计算方面，机器学习技术与可扩展生物资讯学流程的融合，大大提升了解读大规模、复杂、多模态资料的能力。这些工具不仅增强了讯号提取和批次效应校正，还支援预测建模和细胞状态轨迹估计，从而为目标选择和实验设计提供资讯。因此，数据分析正从事后考虑转变为工作流程规划的核心组成部分，这需要对人员和基础设施进行投入。

此外，生态系统正朝向服务导向型发展。仪器製造商越来越多地将仪器与数据分析服务和持续支援捆绑销售，以降低非计算型终端用户的使用门槛。同时，仪器製造商、试剂供应商和软体开发商之间的合作正在打造垂直整合的解决方案，从而简化实验流程。这些变化正在塑造技术提供者和服务机构之间新的竞争格局，并加速单细胞研究成果向临床应用的转化。

2025年关税调整对生命科学领域高价值设备和耗材筹资策略、供应链韧性和供应商选择的影响

影响跨境贸易的政策趋势正为2025年的采购、供应链设计和资本规划带来实际考量。关税调整及相关贸易措施有可能增加设备和特殊试剂的到岸成本，迫使实验室和采购团队重新评估供应商选择、库存策略和总拥有成本（TCO）。为此，各机构普遍优先考虑在地采购，实现供应商多元化，并重新谈判服务合同，以降低价格波动风险并保障计划进度。

除了直接的成本影响外，关税还会影响定序仪、质谱仪和流式细胞仪等高价值设备的供货和前置作业时间。前置作业时间延长会波及研发专案的运作，可能导致关键实验和下游开发里程碑的延误。因此，策略性负责人越来越重视地缘政治风险和进口关税，并将这些因素纳入其长期设备更新周期和资本支出核准中，同时寻求租赁安排和本地维护伙伴关係关係，以确保设备的连续性。

最后，贸易措施将重塑供应商之间的竞争格局。拥有分散式製造地或区域组装中心的公司在保护客户免受关税波动影响方面具有优势，而依赖单一国际供应链的公司则可能面临价格压力，必须自行承担或转嫁这些压力。对终端使用者而言，2025年关税的累积效应凸显了合约弹性、情境规划以及与供应商建立合作关係的重要性。

实用的细分综合分析揭示了设备、化学、计算平台和最终用户需求交叉影响产品开发和购买行为的领域。

细緻的市场区隔架构突显了单细胞多组体学生态系统中值得关注的投资与创新领域。按产品类型划分，市场涵盖耗材和试剂、仪器以及服务。耗材和试剂包括套件和用于稳定样品製备的单一试剂。仪器则涵盖了资料收集的硬体基础：流式细胞仪、质谱仪和定序仪。服务包括数据分析、支援和维护，以确保运行的连续性和分析的严谨性。

从技术角度来看，单细胞基因组学、蛋白质组学、转录组学和空间体学之间的差异凸显了它们各自不同的技术要求和价值提案。单细胞基因体学又细分为诸如scATAC-seq和scDNA-seq等方法，分别用于研究染色质可及性和基因组变异。单细胞蛋白质体学包括无标定蛋白质体学方法和质谱流式细胞仪，后者能够实现大规模蛋白质定量。单细胞转录组学可分为基于液滴和基于微孔板的工作流程，以平衡通量和灵敏度。空间体学整合了成像质谱和空间转录组学，用于原位绘製分子特征图。

应用领域的细分揭示了科学和商业性需求集中的领域。生物标记发现涵盖诊断和预后靶点，疾病研究着重于神经病学和肿瘤学等领域，药物发现和开发则包括先导化合物优化和标靶识别。所有这些都需要专门的实验设计和分析流程。将最终用户分为学术和研究机构（进一步细分为政府实验室和大学）、临床诊断实验室（医院实验室和独立实验室）以及製药和生物技术公司（从生物技术公司到大型製药公司），有助于确定采购优先事项、合规要求和服务预期。工作流程细分凸显了资料分析、样品製备和样本製备的重要性。数据分析本身分为人工智慧/机器学习解决方案和传统生物资讯学工具，而样品製备包括条码试剂套件和cDNA合成试剂。样本製备涵盖从细胞分离到细胞分选技术，这些技术构成了下游数据品质的基础。

综合考虑这些细分层，可以揭示瓶颈出现在哪里，价值累积在哪里，以及策略伙伴关係和能力建设将在哪些方面产生最大影响，从而指导产品开发重点，并指南供应商和服务供应商建立满足端到端工作流程需求的捆绑解决方案。

从区域观点看全球生命科学中心在推动策略重点的采纳驱动因素、基础设施成熟度和合作模式

单细胞多组体学的区域趋势反映了世界各地不同的法规结构、研究重点和商业基础设施。在美洲，蓬勃发展的转化研究活动以及生物技术和製药公司的高度集中，推动了对整合工作流程和先进分析服务的需求，这些服务专注于临床应用和治疗创新。为了将实验室发现转化为临床应用，研究机构通常与产业伙伴密切合作，这更凸显了对可扩展、可重复的方法和全面支援服务的需求。

欧洲、中东和非洲地区呈现出多元化的格局，拥有强大的学术研究基础，以及多样化的法规环境和资金筹措倡议。在一些欧洲市场，公共部门对生命科学的投资以及合作联盟的建立，推动了对开放标准和多机构合作的需求，凸显了互通性和统一通讯协定的重要性。同时，该地区的新兴经济体正致力于能力建设，并推动在地化采用经济高效的工作流程，以弥合基础设施和专业知识方面的差距。

亚太地区正经历快速的自动化应用，这主要得益于不断增长的研发投入、蓬勃发展的生物技术产业以及在地化生产和分析能力的倡议。该地区汇聚了许多高通量学术研究中心和快速成长的生物技术公司，从而推动了对自动化平台、可扩展试剂供应和云端数据分析解决方案的需求。跨境合作和区域伙伴关係也促进了这个充满活力的环境，在这样的环境中，在地化的服务模式和对监管法规的理解对于市场准入和持续成长至关重要。

供应商之间的竞争和伙伴关係动态决定了整合型企业、服务主导模式的采用以及客户价值的持续成长。

单细胞多组体学生态系统中的主要企业在仪器、试剂和分析方面占据互补地位，建构了相互关联的价值链，从而影响创新的轨迹。仪器製造商持续在通量、灵敏度和多模态竞争。服务供应商和分析公司透过连接实验执行和高级计算解读而日益受到重视，使那些缺乏深厚内部生物资讯学专业知识的机构能够最大限度地发挥多模态数据集的价值。

竞争格局正在发生变化，伙伴关係和平台生态系统的重要性日益凸显。提供整合仪器、检验试剂、云端分析等综合解决方案的公司，能够降低终端用户门槛，加速技术普及。同时，专注于高灵敏度蛋白质体学或空间转录组学等细分领域的专业公司，则提供关键创新技术，支援广泛的工作流程。这些专业供应商与平台公司之间的策略合作，往往能够打造出满足特定应用需求的整合解决方案，例如肿瘤学中的生物标记发现或神经病学中的单细胞分析。

此外，投资于使用者培训、可重复性研究和社群参与的公司更有可能培养长期的客户忠诚度。因此，兼顾产品创新、卓越服务和生态系统伙伴关係的企业策略，最有利于确保学术、临床和商业终端用户的持续参与。

为确保工作流程弹性、分析能力和协作途径，从而实现持续的科学影响，各组织应制定以行动为导向的策略重点。

产业和研究领导者必须采取实际行动，才能在有效管理营运复杂性和成本风险的同时，充分发挥单细胞多体学的策略优势。首先，他们应优先投资于端到端的工作流程，将样品製备、文库建构、仪器操作和分析等环节连接起来，从而减少故障点，并加快获得洞见的速度。这意味着选择合作伙伴不仅要考虑组件效能，还要考虑其提供检验、可互通的解决方案以及持续支援的能力。

第二，建构计算生物学和资料管治的内部能力。随着资料集规模和复杂性的成长，能够开发出稳健的流程、标准化的元资料操作和解释框架的机构将从多模态实验中获得更大的价值。培训跨职能团队，使其了解湿实验室的限制和建模方面的考量，将有助于改进实验设计和提高实验的可重复性。第三，将供应链风险评估纳入采购计划，并考虑区域采购、供应商多元化和灵活的合约安排等策略，以降低关税和物流中断的影响。

最后，应推行风险共用、加速创新的合作模式。公私合营、方法标准化联盟以及外部资料共用协定能够降低复杂应用领域的进入门槛，并建立促进跨研究比较的社群标准。透过将投资重点与转化目标结合，各机构可以将单细胞多组体学从一项研究能力转变为一项策略性资产，从而支持长期的科学和商业性目标。

透明、多方面的研究途径整合了专家访谈、技术文献综述和通讯协定检验，以支持实际结论。

该研究结合了与关键专家的面对面访谈、对同行评审文献的系统性回顾，以及对产品、技术、应用、最终用户和工作流程等维度的结构化评估。与实验室主任、采购人员、计算科学家和高级技术主管的对话是了解实验和转化环境中的操作实践、应用驱动因素和未满足需求的资讯来源。这些定性见解辅以方法论文献和供应商技术规范的分析，以确保性能特征和工作流程相容性的准确性。

为确保研究的严谨性，本研究将访谈检验与已记录的产品特性进行交叉验证，并透过独立的第三方评估和社群基准资料对技术能力声明进行三角验证。分析方法强调可重复性，记录了影响最终用户体验的通讯协定差异、数据处理选择和常见故障模式。在整个过程中，研究始终避免对定价或市场规模做出任意假设，而是将重点放在技术能力、营运影响以及相关人员的策略考量上。

最后，在评估采购和实施风险时，也考虑了区域法规和供应链因素。调查方法旨在确保透明度和可重复性，使读者能够清晰地追溯资讯来源与本报告结论之间的联繫。

对技术整合、营运规范和协作模式如何将单细胞洞察转化为应用优势进行策略性综合分析。

单细胞多组体学正处于一个关键的转折点，其方法学的成熟度与生物医学研发的策略需求交汇融合。高性能仪器、精密化学和先进分析技术的整合，使得我们能够更精确地了解细胞状态和交互作用，从而直接影响生物标记的发现、疾病研究和药物研发。然而，要充分发挥这一潜力，需要的不仅是技术的应用；还需要在工作流程、运算能力和稳健的筹资策略进行协同投资。

在各个领域和地区，那些将技术严谨性与营运规范相结合的组织将取得最大成功。这包括采用标准化通讯协定、投资资料管治以及建立能够提供端到端解决方案的伙伴关係。此外，透过在地化策略和灵活的合约结构来应对地缘政治和贸易压力，对于维持业务连续性和控制总体拥有成本至关重要。最终，单细胞多组体学的策略价值不仅取决于其提供的洞见深度，还取决于其加速转化成果以及为那些将其巧妙地整合到研发和临床工作流程中的组织创造永续竞争优势的能力。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合空间转录组学和蛋白​​质组学进行肿瘤异质性的高级分析
  • 一个基于人工智慧的平台，用于全面整合和解读单细胞多体学数据
  • 用于可扩展单细胞蛋白质体学工作流程的高通量微流体自动化技术
  • 利用云端基础的协作流程加速大规模单细胞多体学学研究
  • 单细胞表观基因分析技术的进步有助于阐明调控机制
  • 多模态成像质谱流式细胞仪在单细胞免疫分析应用的兴起
  • 用于个人化医疗的整合式单细胞多体学检测的商业化
  • 单细胞多组体学技术在免疫肿瘤生物标记开发研究的应用日益广泛

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：单细胞多组体学市场（依产品划分）

  • 耗材和试剂
    • 套件
    • 试剂
  • 装置
    • 流式细胞仪
    • 质谱仪
    • 序列器
  • 服务
    • 数据分析服务
    • 支援与维护

9. 按技术分類的单细胞多组体学市场

  • 单细胞基因体学
    • scATAC-seq
    • scDNA-seq
  • 单细胞蛋白质体学
    • 无标定蛋白质体学
    • 质谱流式细胞仪
  • 单细胞转录组学
    • 液滴基底
    • 底板
  • 空间体学
    • 成像质谱
    • 空间转录组学

第十章 单细胞多组体学市场（依应用划分）

  • 生物标记发现
    • 诊断生物标记
    • 预后生物标记
  • 疾病研究
    • 神经病学
    • 肿瘤学
  • 药物发现与开发
    • 先导药物最适化
    • 目标识别

第十一章 单细胞体学市场（依最终用户划分）

  • 学术和研究机构
    • 政府研究机构
    • 大学
  • 临床诊断实验室
    • 医院检查室
    • 独立研究机构
  • 製药和生物技术公司
    • 生技公司
    • 大型製药企业

第十二章：单细胞多组体学市场（依工作流程划分）

  • 数据分析
    • 人工智慧和机器学习解决方案
    • 生物资讯学工具
  • 样品製备
    • 条码套件
    • cDNA合成
  • 样品製备
    • 细胞分离
    • 细胞分选

第十三章：单细胞多组体学市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 单细胞体学市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国单细胞体学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • 10x Genomics, Inc.
    • Illumina, Inc.
    • Bio-Rad Laboratories, Inc.
    • Becton, Dickinson and Company
    • Standard BioTools Inc.
    • NanoString Technologies, Inc.
    • Takara Bio Inc.
    • Mission Bio, Inc.
    • IsoPlexis Corporation
    • Resolve Biosciences Ltd.
Product Code: MRR-7C31448F0BAB

The Single-Cell Multi-Omics Market is projected to grow by USD 7.47 billion at a CAGR of 11.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.18 billion
Estimated Year [2025] USD 3.54 billion
Forecast Year [2032] USD 7.47 billion
CAGR (%) 11.27%

An authoritative overview of how single-cell multi-omics has evolved into a cross-disciplinary platform reshaping research priorities and translational pipelines

Single-cell multi-omics has moved from a niche research curiosity to a cornerstone of modern life sciences, reshaping how researchers interrogate cellular heterogeneity and biological systems. Recent methodological advances have increased resolution across genomic, transcriptomic, proteomic, and spatial layers, enabling integrated views of cells within tissues, developmental processes, and disease states. As a result, the technology suite now supports a broader set of experimental goals-from biomarker discovery and mechanistic studies to target identification and drug optimization-making it an indispensable tool for both academia and industry.

At the same time, adoption dynamics are shifting. Early adopters focused on proof-of-concept experiments and methodological benchmarking, whereas current adopters prioritize throughput, reproducibility, and end-to-end workflows that deliver actionable insights. This maturation has spurred investments in instruments, consumables, sample and library preparation kits, and sophisticated data analysis solutions that leverage AI and advanced bioinformatics. Consequently, stakeholders must navigate not only instrument performance but also vendor ecosystems, data interoperability, and regulatory expectations.

Transitioning from discovery to translational applications introduces new operational complexities and strategic decisions. Organizations must balance the need for high-resolution data with throughput, cost, and downstream analytical capacity. Moreover, cross-disciplinary collaboration between wet-lab scientists, computational biologists, and clinical teams has become essential. This introduction sets the stage for a deeper examination of technological inflection points, regulatory and trade headwinds, segmentation-specific opportunities, regional nuance, and strategic recommendations for leaders seeking to capitalize on single-cell multi-omics advancements.

Critical technological and ecosystem inflection points that are accelerating multimodal integration, throughput, and analytic sophistication across life science workflows

The landscape of single-cell multi-omics is undergoing transformative shifts driven by convergence across instrumentation, chemistry, and computational analytics. Instrument vendors are pursuing higher throughput and integrative modalities that allow simultaneous capture of DNA, RNA, proteins, and spatial context, thereby reducing aggregate experimental costs and accelerating time to insight. Parallel advances in reagents and library preparation chemistry have improved capture efficiency and reduced technical variability, enabling more consistent cross-study comparisons and reproducibility.

On the computational side, the integration of machine learning techniques and scalable bioinformatics pipelines has unlocked the capacity to interpret complex multimodal data at scale. These tools are not only enhancing signal extraction and batch-effect correction but are also enabling predictive modeling and cell-state trajectory inference that inform target selection and experimental design. As a result, data analysis is transitioning from an afterthought to a core element of workflow planning, demanding investments in both personnel and infrastructure.

Additionally, the ecosystem is becoming more service-oriented. Providers increasingly bundle instruments with data analysis services and ongoing support to reduce barriers to adoption among non-computational end users. In parallel, partnerships between instrument manufacturers, reagent suppliers, and software developers are creating vertically integrated offerings that streamline experimental workflows. Taken together, these shifts are accelerating the translation of single-cell insights into clinically relevant applications while creating new competitive dynamics among technology providers and service organizations.

How 2025 tariff shifts are reshaping procurement strategies, supply chain resilience, and vendor selection for high-value instruments and consumables in life sciences

Policy developments affecting cross-border trade have introduced practical considerations for procurement, supply chain design, and capital planning in 2025. Tariff adjustments and related trade measures can increase landed costs for instruments and specialized reagents, prompting laboratories and procurement teams to reassess supplier selection, inventory strategies, and total cost of ownership. In response, organizations often prioritize local sourcing where feasible, diversify supplier bases, or renegotiate service contracts to mitigate price exposure and protect project timelines.

Beyond direct cost impacts, tariffs can influence product availability and lead times for high-value equipment such as sequencers, mass spectrometers, and flow cytometers. Extended lead times have operational repercussions for research programs, potentially delaying critical experiments and downstream development milestones. Consequently, strategic buyers are increasingly factoring geopolitical risk and import duties into long-range equipment replacement cycles and capital expenditure approvals, as well as exploring leasing and local maintenance partnerships to maintain continuity.

Finally, trade measures reshape competitive dynamics among vendors. Firms with decentralized manufacturing footprints or regional assembly centers are better positioned to shield customers from tariff volatility, while companies reliant on single-source international supply chains may face pricing pressure that they must either absorb or pass on. For end users, the cumulative effect of tariffs in 2025 underscores the importance of contract flexibility, scenario planning, and collaborative vendor relationships to sustain research momentum and protect innovation timelines.

A practical segmentation synthesis revealing where instruments, chemistries, computational platforms, and end-user needs converge to shape product development and purchasing behavior

A nuanced segmentation framework provides clarity on where investments and innovation are concentrated across the single-cell multi-omics ecosystem. By product, the market spans consumables and reagents, instruments, and services; consumables and reagents encompass both kits and individual reagents that are critical for consistent sample and library preparation, while instruments cover flow cytometers, mass spectrometers, and sequencers that form the hardware backbone for data acquisition, and services include data analysis and support and maintenance offerings that ensure operational continuity and analytical rigor.

From a technology perspective, distinctions between single-cell genomics, proteomics, transcriptomics, and spatial multi-omics highlight differing technical requirements and value propositions. Single-cell genomics subdivides into modalities such as scATAC-seq and scDNA-seq, each addressing chromatin accessibility and genomic variation respectively; single-cell proteomics includes label-free proteomic approaches and mass cytometry that enable quantitative protein measurement at scale; single-cell transcriptomics differentiates between droplet-based and plate-based workflows that balance throughput and sensitivity; spatial multi-omics integrates imaging mass spectrometry and spatial transcriptomics to map molecular features in situ.

Application segmentation reveals where scientific and commercial demand concentrates. Biomarker discovery spans diagnostic and prognostic targets, disease research centers on areas like neurology and oncology, and drug discovery and development covers lead optimization and target identification, all of which require tailored experimental designs and analytic pipelines. End-user distinctions among academic and research institutes-further described by government labs and universities-clinical diagnostics laboratories-differentiated into hospital labs and independent labs-and pharma and biotech entities-ranging from biotech firms to large pharma-shape purchasing priorities, compliance needs, and service expectations. Workflow segmentation underscores the growing importance of data analysis, library preparation, and sample preparation; data analysis itself bifurcates into AI and ML solutions versus conventional bioinformatics tools, library preparation includes barcoding kits and cDNA synthesis reagents, and sample preparation spans cell isolation and cell sorting techniques that are foundational to downstream data quality.

Together, these segmentation layers illuminate where bottlenecks emerge, where value accrues, and where strategic partnerships or capability building can deliver the greatest return. They also guide product development priorities and inform how vendors and service providers craft bundled solutions to address end-to-end workflow needs.

A regionally informed perspective on adoption drivers, infrastructure maturity, and collaboration models shaping strategic priorities across global life science hubs

Regional dynamics in single-cell multi-omics reflect varying regulatory frameworks, research priorities, and commercial infrastructures across the globe. In the Americas, robust translational research activity and a dense concentration of biotech and pharma companies create a high demand for integrated workflows and advanced analytical services, with an emphasis on clinical translation and therapeutic innovation. Research institutions often collaborate closely with industry partners to move discoveries from bench to clinic, amplifying the need for scalable, reproducible methods and comprehensive support services.

Europe, Middle East & Africa present a heterogeneous landscape where strong academic research hubs coexist with diverse regulatory environments and funding models. In several European markets, public investment in life sciences and collaborative consortia fosters an appetite for open standards and multi-center studies, which accentuates the importance of interoperability and harmonized protocols. Meanwhile, emerging economies within the region are focusing on capacity-building initiatives and local adoption of cost-effective workflows to bridge gaps in infrastructure and expertise.

Asia-Pacific demonstrates rapid adoption driven by expanding research investments, a growing biotechnology industry, and initiatives to localize manufacturing and analytic capabilities. The region's mix of high-throughput academic centers and rapidly scaling biotech firms accelerates demand for automated platforms, scalable reagent supplies, and cloud-enabled data analysis solutions. Cross-border collaborations and regional partnerships are also contributing to a dynamic environment where localized service models and regulatory familiarity are increasingly important for market entry and sustained growth.

Competitive positioning and partnership dynamics among vendors that determine which firms drive integration, service-led adoption, and sustained customer value

Key companies shaping the single-cell multi-omics ecosystem occupy complementary positions across instruments, reagents, and analytics, creating interconnected value chains that influence innovation trajectories. Instrument manufacturers continue to compete on throughput, sensitivity, and multimodal integration, while reagent suppliers differentiate through chemistry improvements that enhance capture efficiency and reduce technical noise. Service providers and analytics firms are gaining prominence by bridging experimental execution with advanced computational interpretation, thereby enabling organizations without deep in-house bioinformatics expertise to realize the full value of multimodal datasets.

Competitive dynamics increasingly favor partnerships and platform ecosystems. Companies that offer comprehensive bundles-combining instruments, validated reagents, cloud-enabled analytics, and support-reduce friction for end users and accelerate adoption. At the same time, specialist firms that focus on niche capabilities, such as high-sensitivity proteomics or spatial transcriptomics, provide critical innovations that feed into broader workflows. Strategic collaborations between these specialist providers and platform companies often yield integrated solutions that address specific application needs, such as biomarker discovery in oncology or single-cell profiling in neurology.

Moreover, companies that invest in user training, reproducibility studies, and community engagement are more likely to cultivate long-term customer loyalty. As a result, corporate strategies that balance product innovation with service excellence and ecosystem partnerships are best positioned to capture sustained engagement from academic, clinical, and commercial end users.

Action-oriented strategic priorities for organizations to secure workflow resilience, analytic capability, and collaborative pathways for sustainable scientific impact

Leaders in industry and research institutions must act deliberately to capture the strategic benefits of single-cell multi-omics while controlling operational complexity and cost exposure. First, prioritize investments in end-to-end workflows that link sample preparation, library construction, instrumentation, and analytics to reduce failure points and accelerate time to insight. This means selecting partners based not only on component performance but also on their ability to deliver validated, interoperable solutions and ongoing support.

Second, build internal capabilities in computational biology and data governance. As datasets grow in volume and complexity, organizations that develop robust pipelines, standardized metadata practices, and interpretive frameworks will extract greater value from multimodal experiments. Training cross-functional teams to understand both wet-lab constraints and modeling considerations will enhance experimental design and reproducibility. Third, incorporate supply chain risk assessments into procurement planning and consider strategies such as regional sourcing, vendor diversification, and flexible contracting to mitigate tariff and logistics disruptions.

Finally, pursue collaborative models that share risk and accelerate innovation. Public-private partnerships, consortia for method standardization, and external data-sharing agreements can lower barriers to entry for complex applications and produce community standards that facilitate cross-study comparisons. By aligning investment priorities with translational goals, organizations can transform single-cell multi-omics from a research capability into a strategic asset that supports long-term scientific and commercial objectives.

A transparent, multi-source research approach combining expert interviews, technical literature review, and protocol validation to underpin actionable conclusions

This research synthesizes primary expert interviews, a systematic review of peer-reviewed literature, and a structured assessment of product, technology, application, end-user, and workflow dimensions. Primary inputs include discussions with laboratory directors, procurement leaders, computational scientists, and senior technology executives to capture operational realities, adoption drivers, and unmet needs across experimental and translational settings. These qualitative insights were complemented by an analysis of methodological literature and vendor technical specifications to ensure accuracy on performance attributes and workflow compatibility.

To ensure rigor, the study applied cross-validation between interview insights and documented product characteristics, and it triangulated claims about technology capabilities with independent third-party evaluations and community benchmarks. The analytic approach emphasized reproducibility by documenting protocol variants, data processing choices, and common failure modes that influence end-user experiences. Throughout, attention was paid to avoiding proprietary assumptions about pricing or market sizing; the focus remained on technology capabilities, operational implications, and strategic considerations for stakeholders.

Finally, sensitivity to regional regulatory and supply chain factors informed the assessment of procurement and deployment risks. The methodology is designed to be transparent and reproducible, providing readers with clear traceability between source inputs and the conclusions drawn in this report.

A strategic synthesis highlighting how technical integration, operational discipline, and collaborative models convert single-cell insights into translational advantage

Single-cell multi-omics stands at an inflection point where methodological maturity converges with strategic necessity for biomedical research and development. The integration of high-performance instruments, refined chemistries, and advanced analytics is enabling more precise interrogation of cellular states and interactions, with direct implications for biomarker discovery, disease research, and drug development. However, realizing this potential requires more than technology acquisition; it demands coordinated investments in workflows, computational talent, and resilient procurement strategies.

Looking across segments and regions, the most successful adopters will be those that couple technical rigor with operational discipline: implementing standardized protocols, investing in data governance, and engaging in partnerships that deliver end-to-end solutions. Additionally, responsiveness to geopolitical and trade-related pressures through localized strategies and flexible contracting will be essential to preserve continuity and manage total cost of ownership. Ultimately, the strategic value of single-cell multi-omics will be measured not only by the depth of insight it provides but by its ability to accelerate translational outcomes and create sustainable competitive advantage for organizations that integrate it thoughtfully into their R&D and clinical workflows.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of spatial transcriptomics with proteogenomics for enhanced tumor heterogeneity analysis
  • 5.2. AI-driven platforms for comprehensive single-cell multi-omics data integration and interpretation
  • 5.3. High-throughput microfluidics automation enabling scalable single-cell proteogenomics workflows
  • 5.4. Cloud-based collaborative pipelines accelerating large-scale single-cell multi-omics research
  • 5.5. Advancements in single-cell epigenomic profiling techniques for uncovering regulatory mechanisms
  • 5.6. Emergence of multimodal imaging mass cytometry in single-cell immune profiling applications
  • 5.7. Commercialization of integrated single-cell multi-omics assays for personalized medicine discovery
  • 5.8. Expansion of single-cell multi-omics adoption in immuno-oncology biomarker development studies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single-Cell Multi-Omics Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Kits
    • 8.1.2. Reagents
  • 8.2. Instruments
    • 8.2.1. Flow Cytometers
    • 8.2.2. Mass Spectrometers
    • 8.2.3. Sequencers
  • 8.3. Services
    • 8.3.1. Data Analysis Services
    • 8.3.2. Support & Maintenance

9. Single-Cell Multi-Omics Market, by Technology

  • 9.1. Single-cell Genomics
    • 9.1.1. scATAC-seq
    • 9.1.2. scDNA-seq
  • 9.2. Single-cell Proteomics
    • 9.2.1. Label-free Proteomics
    • 9.2.2. Mass Cytometry
  • 9.3. Single-cell Transcriptomics
    • 9.3.1. Droplet-based
    • 9.3.2. Plate-based
  • 9.4. Spatial Multi-omics
    • 9.4.1. Imaging Mass Spectrometry
    • 9.4.2. Spatial Transcriptomics

10. Single-Cell Multi-Omics Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Diagnostic Biomarkers
    • 10.1.2. Prognostic Biomarkers
  • 10.2. Disease Research
    • 10.2.1. Neurology
    • 10.2.2. Oncology
  • 10.3. Drug Discovery & Development
    • 10.3.1. Lead Optimization
    • 10.3.2. Target Identification

11. Single-Cell Multi-Omics Market, by End User

  • 11.1. Academic & Research Institute
    • 11.1.1. Government Labs
    • 11.1.2. Universities
  • 11.2. Clinical Diagnostics Laboratories
    • 11.2.1. Hospital Labs
    • 11.2.2. Independent Labs
  • 11.3. Pharma & Biotech
    • 11.3.1. Biotech Firms
    • 11.3.2. Large Pharma

12. Single-Cell Multi-Omics Market, by Workflow

  • 12.1. Data Analysis
    • 12.1.1. AI & ML Solutions
    • 12.1.2. Bioinformatics Tools
  • 12.2. Library Preparation
    • 12.2.1. Barcoding Kits
    • 12.2.2. cDNA Synthesis
  • 12.3. Sample Preparation
    • 12.3.1. Cell Isolation
    • 12.3.2. Cell Sorting

13. Single-Cell Multi-Omics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Single-Cell Multi-Omics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Single-Cell Multi-Omics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. 10x Genomics, Inc.
    • 16.3.2. Illumina, Inc.
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. Becton, Dickinson and Company
    • 16.3.5. Standard BioTools Inc.
    • 16.3.6. NanoString Technologies, Inc.
    • 16.3.7. Takara Bio Inc.
    • 16.3.8. Mission Bio, Inc.
    • 16.3.9. IsoPlexis Corporation
    • 16.3.10. Resolve Biosciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SINGLE-CELL MULTI-OMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SINGLE-CELL MULTI-OMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SINGLE-CELL MULTI-OMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCATAC-SEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SCDNA-SEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL PROTEOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LABEL-FREE PROTEOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SINGLE-CELL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DROPLET-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PLATE-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL MULTI-OMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY IMAGING MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DIAGNOSTIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOTECH FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY AI & ML SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL SINGLE-CELL MULTI-OMICS MARKET SIZE, BY BIOINFORMATICS TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL SI